Video

Risk Stratification of Patients with Prostate Cancer

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC, FACS

Michael Cookson, MD, MMHC, explains the NCCN criteria used to stratify patients with clinically localized prostate cancer into risk groups.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Ruben Olivares, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke
The level II code A9616 will be effective starting on October 1, 2025.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Study shows favorable outcomes with guideline-based treatment for localized prostate cancer
July 14th 2025

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

Hannah Clarke
“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor
According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.
FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke
The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
© 2025 MJH Life Sciences

All rights reserved.